Survival Boost With Neoadjuvant Chemo-Immunotherapy in NSCLC Survival Boost With Neoadjuvant Chemo-Immunotherapy in NSCLC

Adding neoadjuvant nivolumab to chemotherapy in stage IIIA/IIIB non ¬–small cell lung cancer markedly improves both progression-free and overall survival over neoadjuvant chemotherapy alone.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news